For the year ending 2025-12-31, ANVS had $8,980,422 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -28,854,197 |
| Stock-based compensation expense | 1,797,676 |
| Change in fair value of warrants | -142,000 |
| Prepaid expenses and other current assets | -1,824,430 |
| Accounts payable | 284,542 |
| Accrued expenses | -530,154 |
| Net cash used in operating activities | -25,619,703 |
| Proceeds from issuance of common stock, warrants, and pre-funded warrants, net | 34,598,126 |
| Proceeds from exercise of common stock options, net | 1,999 |
| Net cash provided by financing activities | 34,600,125 |
| Net increase in cash and cash equivalents | 8,980,422 |
| Cash and cash equivalents, beginning of period | 10,551,916 |
| Cash and cash equivalents, end of period | 19,532,338 |
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)